Interv Akut Kardiol. 2006;5(3):116-121

MANAGEMENT OF PATIENTS AFTER HEART TRANSPLANTATION

doc. MUDr. Ivan Málek CSc
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

The article presents a brief overview of the management of patients after heart transplantation and the solving of possible problems which can be encountered in this special clinical situation. It may serve as a basic information source for cardiologists who are not routinely faced with these issues. To obtain more detailed information references are listed, mainly from the home literature.

Keywords: Key words: transplantation, rejection, immunosuppressives, coronary vasculopathy.

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek I. MANAGEMENT OF PATIENTS AFTER HEART TRANSPLANTATION. Interv Akut Kardiol. 2006;5(3):116-121.
Download citation

References

  1. Málek I. Transplantace srdce. Pohled kardiologa. 1. vyd. Praha: Triton, 2004. 108 s.
  2. Kettner J. Mechanické podpory krevního oběhu. Cor Vasa 2003; 45: 437-443.
  3. Kakáč J, Málek I, Hrnčárek M, et al. Testování plicní hypertenze u kandidátů ortotopické transplantace srdce pomocí prostaglandinu E1. Cor Vasa 1996; 38, 5: 251-257.
  4. Gebauerová M, Jandová R, Málek I. a spol.: Obraz nemocného po transplantaci srdce. Cor Vasa 1993; 35: 258-262.
  5. Vymětalová Y, Málek I.: Akutní rejekce po transplantaci srdce. Edukační příloha časopisu Kardiologická revue na téma, ,Pacient po transplantaci srdce". Kardiofórum 2005; 3(4): 12-15.
  6. Billingham ME, Cary NRB, Hammond EH et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. Heart Transplant. 1990: 9: 587-593.
  7. Kocík M, Dufková B, Málek I. Koronární nemoc srdečního štěpu. Edukační příloha časopisu Kardiologická revue na téma, ,Pacient po transplantaci srdce". Kardiofórum 2005; 3(4): 25-28.
  8. Hegarová M., Málek I.: Imunosupresiva po transplantaci srdce. Edukační příloha časopisu Kardiologická revue na téma, ,Pacient po transplantaci srdce". Kardiofórum 2005; 3(4): 16-21.
  9. Barnard CN. A human cardiac transplant: an interim report of successful operation performed at Groote Schuur Hospital, Capetown. S Afr Med J. 1967; 41: 1271-1274.
  10. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report 2005. J Heart Lung Transplantation 2005; 24, 8: 956-967. Go to original source... Go to PubMed...
  11. Hošková L, Málek I, Šedivý J, et al. Lékové interakce cyclosporinu A. Cor Vasa 2002; 44: 481-486.
  12. Jandová R, Fabián J. Výskyt systémové hypertenze po ortotopické transplantaci srdce. Čas Lék čes. 1990; 129: 16-19.
  13. Viklický O, Podzimková M, Matl I, et al. Renal function in cyclosporine-treated heart transplant recipients long-term follow-up. Cor Vasa 1999; 41: 131-134.
  14. Hošková L, Viklický O, Málek I. Renální dysfunkce u pacientů po transplantaci srdce. Edukační příloha časopisu Kardiologická revue na téma, ,Pacient po transplantaci srdce". Kardiofórum 2005; 3(4): 22-24.
  15. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplantation 2005; 24, 11: 1736-1740. Go to original source... Go to PubMed...
  16. Špinarová L, Toman J. Fluvastatin u pacientů po transplantaci srdce. Vnitřní Lék. 1998; 44: 13-16.
  17. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349, 9: 847-858. Go to original source... Go to PubMed...
  18. Podzimková M, Gebauerová M, Málek I, et al. Infekční komplikace nemocných po transplantaci srdce. Cor Vasa 1993; 82: 620-623.
  19. Hošková L, Málek I, Podzimková M, et al. Nádorová onemocnění u pacientů po transplantaci srdce. Cor Vasa 2002; 44, 2: 77-80.




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.